SCHEMBL5887165

SCHEMBL5887165

COc1ccc(C2=C(F)[CH]CC=C2c2ccc(Cl)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 1/20 0.37
PTGS1 P23219 3/20 0.36
BACE1 P56817 1/20 0.36
ALOX5 P09917 1/20 0.35
GLA P06280 1/20 0.35
PTGS2 P35354 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
THPO P40225 1/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
HIF1A Q16665 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSP90AA1 P07900 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887349 0.87 ACHE (0.44) NPC1RAB9ASMN1; SMN2PTGS1BACE1
SCHEMBL5887461 0.85 NPC1 (0.39) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887257 0.84 ALKBH3 (0.40) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887297 0.84 NPC1 (0.38) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887097 0.77 ALOX5 (0.40) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887086 0.75 ALKBH3 (0.46) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887134 0.75 ALOX5 (0.39) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887317 0.75 ALOX5 (0.39) NPC1RAB9ASMN1; SMN2HPGDBACE1
SCHEMBL5887556 0.74 ALOX5 (0.40) NPC1RAB9ASMN1; SMN2HPGDALOX5
SCHEMBL5887664 0.72 ALOX5 (0.39) NPC1RAB9ASMN1; SMN2HPGDALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R NPC1 1831/4885RAB9A 1054/4885SMN1; SMN2 1459/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R NPC1 2930/4885RAB9A 1724/4885SMN1; SMN2 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.